The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer
Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifi...
Saved in:
Published in | Cancer research (Chicago, Ill.) Vol. 65; no. 15; pp. 6660 - 6667 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Philadelphia, PA
American Association for Cancer Research
01.08.2005
|
Subjects | |
Online Access | Get full text |
ISSN | 0008-5472 1538-7445 |
DOI | 10.1158/0008-5472.CAN-04-3478 |
Cover
Abstract | Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein–specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR. |
---|---|
AbstractList | Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein-specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR.Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein-specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR. Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer. For more than two decades, these two important but not clearly related aspects in the biology of cancer have been extensively studied. Specifically, P-glycoprotein and CD44 have been characterized and are known to be determinants of multidrug resistance (MDR) and metastases. Despite this body of knowledge, few reports have linked the two phenotypes and only recently have there been reasons to suspect a direct connection. In this report, we show that a novel physical and genetic interaction between CD44s and P-glycoprotein is in part responsible for the correlation between MDR and invasive potential in cancer cells. P-glycoprotein–specific substrates that interfere with its function reduced in vitro invasion, migration, and the physical colocalization of CD44s and P-glycoprotein. CD44 expression in sensitive cells promoted the expression of P-glycoprotein and the MDR phenotype. RNA interference of MDR1 inhibited the rate of cell migration. These data indicate that there is a close interaction between CD44 and P-glycoprotein that results in the concurrent expression and modulation of two malignant phenotypes, invasion and MDR. |
Author | Apolito, Kevin Shih, Weichung J. Muthukumaran, Neelakandan Miletti-González, Karl E. Chen, Shiling Saglimbeni, Giuseppa N. Wu, Xiaohua Yang, Jinming Hait, William N. Rodríguez-Rodríguez, Lorna |
Author_xml | – sequence: 1 givenname: Karl E. surname: Miletti-González fullname: Miletti-González, Karl E. – sequence: 2 givenname: Shiling surname: Chen fullname: Chen, Shiling – sequence: 3 givenname: Neelakandan surname: Muthukumaran fullname: Muthukumaran, Neelakandan – sequence: 4 givenname: Giuseppa N. surname: Saglimbeni fullname: Saglimbeni, Giuseppa N. – sequence: 5 givenname: Xiaohua surname: Wu fullname: Wu, Xiaohua – sequence: 6 givenname: Jinming surname: Yang fullname: Yang, Jinming – sequence: 7 givenname: Kevin surname: Apolito fullname: Apolito, Kevin – sequence: 8 givenname: Weichung J. surname: Shih fullname: Shih, Weichung J. – sequence: 9 givenname: William N. surname: Hait fullname: Hait, William N. – sequence: 10 givenname: Lorna surname: Rodríguez-Rodríguez fullname: Rodríguez-Rodríguez, Lorna |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16988943$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/16061646$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkUtP3DAURi0EKsPQnwDypuxCr-NHHHWFwlPipYqujeNxilEmHmwPaP59nTKUig3ywvqk81nX9-ygzcEPFqE9AoeEcPkdAGTBWVUeNkfXBbCCskpuoAnhVBYVY3wTTf4x22gnxsccOQH-BW0TAYIIJibo_u7B4uaYMfzTGrtIPuCLIdmgTYr4xaUHfFuc9SvjF8En6wacPL4Nfp4Dbmzf4yv3O-jk_ID1MMvdZx3HkMlGD8aGXbTV6T7ar-t7in6dntw158XlzdlFc3RZGAZlKoQGA7O6azU1kpqay1LWpOpa1lkpLJRtbaBjtAVSkjp3KtOWNbQzzkshpaRTdPD6bh70aWljUnMXTZ5QD9YvoxKSUcGAfAqSigEdzxTtr8FlO7cztQhursNKvS0vA9_WgI5G913IH3bxP66WsmY0c_yVM8HHGGz3joAaZapRlBpFqSxTAVOjzNz78aFnXPq76xS06z9p_wHctqIm |
CODEN | CNREA8 |
CitedBy_id | crossref_primary_10_1016_j_apsb_2023_03_024 crossref_primary_10_1002_ijc_24573 crossref_primary_10_1007_s13277_016_5294_5 crossref_primary_10_1080_14397595_2017_1341458 crossref_primary_10_1002_ijc_23122 crossref_primary_10_1074_jbc_M800109200 crossref_primary_10_2217_fon_13_230 crossref_primary_10_1091_mbc_e10_06_0489 crossref_primary_10_1136_rmdopen_2016_000423 crossref_primary_10_3390_molecules27123714 crossref_primary_10_1007_s10330_006_0465_2 crossref_primary_10_1016_j_critrevonc_2018_09_017 crossref_primary_10_1038_sj_bjc_6605839 crossref_primary_10_3109_1061186X_2012_702767 crossref_primary_10_1021_acs_molpharmaceut_9b00189 crossref_primary_10_1080_2162402X_2015_1108513 crossref_primary_10_1158_0008_5472_CAN_08_2491 crossref_primary_10_1158_1078_0432_CCR_13_1536 crossref_primary_10_1111_jebm_12434 crossref_primary_10_1002_pmic_201800165 crossref_primary_10_1007_s12262_012_0616_3 crossref_primary_10_1248_yakushi_22_00108 crossref_primary_10_18632_oncotarget_4763 crossref_primary_10_1007_s00280_008_0684_z crossref_primary_10_1016_j_jbc_2024_107299 crossref_primary_10_1016_j_apsb_2024_01_007 crossref_primary_10_1021_nn501223q crossref_primary_10_1177_0271678X16671147 crossref_primary_10_1016_j_apsusc_2015_01_204 crossref_primary_10_3109_10428194_2011_572323 crossref_primary_10_3389_fonc_2020_589601 crossref_primary_10_1186_1471_2407_13_476 crossref_primary_10_18632_oncotarget_5290 crossref_primary_10_18632_oncotarget_15879 crossref_primary_10_1002_mc_22376 crossref_primary_10_1016_j_ajpath_2024_12_004 crossref_primary_10_1002_mc_22021 crossref_primary_10_1016_j_bbrc_2008_05_012 crossref_primary_10_1016_j_jddst_2019_01_042 crossref_primary_10_1016_j_tranon_2024_102168 crossref_primary_10_1007_s10330_006_0477_y crossref_primary_10_1254_jphs_09323FP crossref_primary_10_3389_fimmu_2015_00201 crossref_primary_10_1007_s11033_019_05058_1 crossref_primary_10_1007_s11523_012_0247_4 crossref_primary_10_1158_1541_7786_MCR_15_0466 crossref_primary_10_12677_WJCR_2023_134022 crossref_primary_10_1016_j_canlet_2015_03_034 crossref_primary_10_1016_j_bcp_2013_11_003 crossref_primary_10_1177_2058739219845155 crossref_primary_10_1016_j_semcancer_2008_03_009 crossref_primary_10_1021_acs_bioconjchem_5b00551 crossref_primary_10_1016_j_taap_2022_115887 crossref_primary_10_3389_fonc_2014_00220 crossref_primary_10_1016_j_yexcr_2006_08_030 crossref_primary_10_2147_OTT_S286639 crossref_primary_10_3390_cancers16244187 crossref_primary_10_1007_s11060_016_2058_4 crossref_primary_10_1158_1541_7786_MCR_05_0232 crossref_primary_10_1016_j_semcdb_2015_03_009 crossref_primary_10_1371_journal_pgen_1001383 crossref_primary_10_1136_ijgc_2021_003316 crossref_primary_10_1038_srep11365 crossref_primary_10_1002_smll_202003309 crossref_primary_10_1016_j_biocel_2018_07_003 crossref_primary_10_3390_cancers13225644 crossref_primary_10_3892_or_2012_1951 crossref_primary_10_3389_fcell_2023_1124960 crossref_primary_10_1111_jgh_13069 crossref_primary_10_1007_s10529_010_0423_5 crossref_primary_10_1007_s00441_009_0780_3 crossref_primary_10_3892_ijo_2015_3299 crossref_primary_10_1074_jbc_M111_318774 crossref_primary_10_3892_ol_2013_1321 crossref_primary_10_1016_j_yexmp_2014_12_001 crossref_primary_10_1111_jcmm_13810 crossref_primary_10_1111_ijlh_13455 crossref_primary_10_1038_srep08509 crossref_primary_10_3390_molecules21030290 crossref_primary_10_1080_1040841X_2019_1607248 crossref_primary_10_1158_1078_0432_CCR_09_0479 crossref_primary_10_2174_1568009620666200506110850 crossref_primary_10_1038_s12276_017_0008_7 crossref_primary_10_1002_ar_24147 crossref_primary_10_1158_1078_0432_CCR_06_1307 crossref_primary_10_1002_jcb_28948 crossref_primary_10_1016_j_ygyno_2019_10_021 crossref_primary_10_1038_nrc2789 crossref_primary_10_3390_ijms22063199 crossref_primary_10_1038_sj_jid_5701082 crossref_primary_10_3892_ijmm_2018_3381 crossref_primary_10_1016_j_matbio_2018_04_012 crossref_primary_10_1038_sj_bjc_6605185 crossref_primary_10_1002_iub_2669 crossref_primary_10_1007_s10549_011_1692_y crossref_primary_10_1002_gcc_20492 crossref_primary_10_1016_j_bbadis_2024_167549 crossref_primary_10_1038_s41598_019_46700_z crossref_primary_10_1158_1078_0432_CCR_14_2141 crossref_primary_10_1016_j_bbcan_2010_06_004 crossref_primary_10_1016_j_biomaterials_2014_12_030 crossref_primary_10_1155_2012_504918 crossref_primary_10_1007_s13277_015_4755_6 crossref_primary_10_1016_j_leukres_2010_02_020 crossref_primary_10_3390_ijms17101718 crossref_primary_10_4103_ijpvm_IJPVM_135_20 crossref_primary_10_1042_BST20150137 crossref_primary_10_1186_bcr2111 crossref_primary_10_1074_jbc_M109_027466 crossref_primary_10_3389_fcell_2018_00097 crossref_primary_10_1186_scrt13 crossref_primary_10_1080_1061186X_2017_1289538 crossref_primary_10_3390_ijms241310627 crossref_primary_10_1038_nrc3023 crossref_primary_10_1186_1471_2407_11_290 crossref_primary_10_1002_1878_0261_13551 crossref_primary_10_3390_jcm7100330 crossref_primary_10_1016_j_gde_2005_12_008 crossref_primary_10_1016_j_canlet_2008_12_015 crossref_primary_10_1038_sj_onc_1209724 crossref_primary_10_1007_s00432_015_2029_8 crossref_primary_10_1007_s10047_012_0644_6 crossref_primary_10_1158_1078_0432_CCR_09_2317 crossref_primary_10_1016_j_pharmthera_2008_04_008 crossref_primary_10_1021_mp500435s crossref_primary_10_4137_CGM_S3716 crossref_primary_10_1245_s10434_009_0395_7 crossref_primary_10_1158_0008_5472_CAN_09_0143 crossref_primary_10_1093_noajnl_vdab030 crossref_primary_10_3390_ijms161024772 crossref_primary_10_3390_cells8101150 crossref_primary_10_1016_j_drup_2008_04_002 crossref_primary_10_1007_s12015_016_9660_x crossref_primary_10_1111_j_1751_553X_2009_01149_x crossref_primary_10_1093_annonc_mdl074 crossref_primary_10_1016_j_heliyon_2022_e11171 crossref_primary_10_1371_journal_pone_0000243 crossref_primary_10_1038_sj_emboj_7601039 crossref_primary_10_3390_biomedicines10020414 crossref_primary_10_1111_j_1447_0756_2006_00422_x crossref_primary_10_3390_ijms24087331 crossref_primary_10_1016_j_heliyon_2022_e09777 crossref_primary_10_3402_jev_v3_24384 crossref_primary_10_2217_epi_2016_0030 crossref_primary_10_1177_0271678X18767748 crossref_primary_10_1016_j_ajpath_2013_01_019 crossref_primary_10_1007_s13277_011_0155_8 crossref_primary_10_3390_ijms23158616 crossref_primary_10_1002_hep_22704 crossref_primary_10_1134_S0006297918070015 crossref_primary_10_1080_10408398_2018_1551778 |
Cites_doi | 10.1007/BF00692343 10.1002/path.1400 10.1073/pnas.89.24.12160 10.1002/ijc.2910430121 10.1016/0092-8674(90)90694-A 10.1002/jcp.1041630314 10.1007/BF00665804 10.1016/S0065-230X(08)60101-3 10.1101/gad.13.1.35 10.1080/0031302031000150524 10.1016/S0959-8049(01)00086-7 10.1074/jbc.C300173200 10.1158/1078-0432.CCR-03-0517 10.1016/S0006-291X(86)80136-X 10.1124/mol.66.2.268 10.1158/1078-0432.CCR-03-0610 10.1172/JCI200316200 10.1016/S0014-5793(00)01087-5 10.1200/JCO.1990.8.4.689 10.1111/j.1349-7006.2001.tb01162.x 10.1007/s002800050449 10.1038/sj.onc.1206948 10.1016/S0006-2952(97)82451-3 10.1093/jnci/83.2.111 10.1074/jbc.273.1.338 10.1158/0008-5472.CAN-03-2832 |
ContentType | Journal Article |
Copyright | 2005 INIST-CNRS |
Copyright_xml | – notice: 2005 INIST-CNRS |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7TO H94 7X8 |
DOI | 10.1158/0008-5472.CAN-04-3478 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef MEDLINE Oncogenes and Growth Factors Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1538-7445 |
EndPage | 6667 |
ExternalDocumentID | 16061646 16988943 10_1158_0008_5472_CAN_04_3478 |
Genre | Research Support, U.S. Gov't, P.H.S Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
GrantInformation_xml | – fundername: NCI NIH HHS grantid: CA 72720 – fundername: NCI NIH HHS grantid: CA 66077 |
GroupedDBID | --- -ET .55 .GJ 18M 29B 2WC 34G 39C 3O- 53G 5GY 5RE 5VS 6J9 8WZ A6W AAFWJ AAJMC AAYXX ABOCM ACGFO ACIWK ACPRK ACSVP ADBBV ADCOW AENEX AETEA AFFNX AFHIN AFOSN AFRAH AFUMD AI. ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW C1A CITATION CS3 DIK DU5 EBS EJD F5P FRP GX1 H13 IH2 KQ8 L7B LSO MVM OHT OK1 P0W P2P PQQKQ RCR RHI RNS SJN TR2 UDS VH1 W2D W8F WH7 WHG WOQ X7M XJT YKV YZZ ZCG ZGI ADNWM D0S IQODW J5H CGR CUY CVF ECM EIF NPM RHF VXZ 7TO H94 7X8 |
ID | FETCH-LOGICAL-c402t-6a0c0d9fba3c83c95828917fb4fe86e02b9c0f43b01219c407cb290bd55268883 |
ISSN | 0008-5472 |
IngestDate | Fri Sep 05 04:23:18 EDT 2025 Thu Sep 04 18:58:45 EDT 2025 Wed Feb 19 01:53:58 EST 2025 Mon Jul 21 09:12:23 EDT 2025 Tue Jul 01 01:17:41 EDT 2025 Thu Apr 24 23:10:56 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 15 |
Keywords | Antineoplastic agent Cell motility Phenotype Multiple resistance P Glycoprotein Metastasis Malignant tumor Invasion Cell migration Biological receptor |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c402t-6a0c0d9fba3c83c95828917fb4fe86e02b9c0f43b01219c407cb290bd55268883 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 16061646 |
PQID | 17403030 |
PQPubID | 23462 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_68436401 proquest_miscellaneous_17403030 pubmed_primary_16061646 pascalfrancis_primary_16988943 crossref_primary_10_1158_0008_5472_CAN_04_3478 crossref_citationtrail_10_1158_0008_5472_CAN_04_3478 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2005-08-01 |
PublicationDateYYYYMMDD | 2005-08-01 |
PublicationDate_xml | – month: 08 year: 2005 text: 2005-08-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | Philadelphia, PA |
PublicationPlace_xml | – name: Philadelphia, PA – name: United States |
PublicationTitle | Cancer research (Chicago, Ill.) |
PublicationTitleAlternate | Cancer Res |
PublicationYear | 2005 |
Publisher | American Association for Cancer Research |
Publisher_xml | – name: American Association for Cancer Research |
References | 2023011120191192500_B30 2023011120191192500_B31 2023011120191192500_B10 2023011120191192500_B32 2023011120191192500_B11 2023011120191192500_B33 2023011120191192500_B12 2023011120191192500_B34 2023011120191192500_B13 2023011120191192500_B35 2023011120191192500_B14 2023011120191192500_B36 2023011120191192500_B15 2023011120191192500_B37 2023011120191192500_B16 2023011120191192500_B38 2023011120191192500_B17 2023011120191192500_B39 2023011120191192500_B29 2023011120191192500_B1 2023011120191192500_B2 2023011120191192500_B3 2023011120191192500_B4 2023011120191192500_B5 2023011120191192500_B6 2023011120191192500_B7 2023011120191192500_B8 2023011120191192500_B9 2023011120191192500_B20 2023011120191192500_B21 2023011120191192500_B22 2023011120191192500_B23 2023011120191192500_B24 2023011120191192500_B25 2023011120191192500_B26 2023011120191192500_B27 2023011120191192500_B28 2023011120191192500_B18 2023011120191192500_B19 |
References_xml | – ident: 2023011120191192500_B17 doi: 10.1007/BF00692343 – ident: 2023011120191192500_B26 – ident: 2023011120191192500_B39 doi: 10.1002/path.1400 – ident: 2023011120191192500_B9 doi: 10.1073/pnas.89.24.12160 – ident: 2023011120191192500_B35 doi: 10.1002/ijc.2910430121 – ident: 2023011120191192500_B6 doi: 10.1016/0092-8674(90)90694-A – ident: 2023011120191192500_B31 doi: 10.1002/jcp.1041630314 – ident: 2023011120191192500_B12 doi: 10.1007/BF00665804 – ident: 2023011120191192500_B2 – ident: 2023011120191192500_B7 doi: 10.1016/S0065-230X(08)60101-3 – ident: 2023011120191192500_B37 – ident: 2023011120191192500_B14 – ident: 2023011120191192500_B32 doi: 10.1101/gad.13.1.35 – ident: 2023011120191192500_B15 doi: 10.1080/0031302031000150524 – ident: 2023011120191192500_B16 – ident: 2023011120191192500_B38 doi: 10.1016/S0959-8049(01)00086-7 – ident: 2023011120191192500_B5 doi: 10.1074/jbc.C300173200 – ident: 2023011120191192500_B28 doi: 10.1158/1078-0432.CCR-03-0517 – ident: 2023011120191192500_B23 – ident: 2023011120191192500_B25 – ident: 2023011120191192500_B21 – ident: 2023011120191192500_B18 doi: 10.1016/S0006-291X(86)80136-X – ident: 2023011120191192500_B22 doi: 10.1124/mol.66.2.268 – ident: 2023011120191192500_B3 doi: 10.1158/1078-0432.CCR-03-0610 – ident: 2023011120191192500_B33 doi: 10.1172/JCI200316200 – ident: 2023011120191192500_B19 doi: 10.1016/S0014-5793(00)01087-5 – ident: 2023011120191192500_B27 – ident: 2023011120191192500_B1 – ident: 2023011120191192500_B11 doi: 10.1200/JCO.1990.8.4.689 – ident: 2023011120191192500_B29 doi: 10.1111/j.1349-7006.2001.tb01162.x – ident: 2023011120191192500_B36 – ident: 2023011120191192500_B24 doi: 10.1007/s002800050449 – ident: 2023011120191192500_B10 doi: 10.1038/sj.onc.1206948 – ident: 2023011120191192500_B20 doi: 10.1016/S0006-2952(97)82451-3 – ident: 2023011120191192500_B34 – ident: 2023011120191192500_B13 doi: 10.1093/jnci/83.2.111 – ident: 2023011120191192500_B30 – ident: 2023011120191192500_B8 doi: 10.1074/jbc.273.1.338 – ident: 2023011120191192500_B4 doi: 10.1158/0008-5472.CAN-03-2832 |
SSID | ssj0005105 |
Score | 2.292404 |
Snippet | Invasion and metastases of cancer cells and the development of resistance to anticancer therapies are the main causes of morbidity and mortality from cancer.... |
SourceID | proquest pubmed pascalfrancis crossref |
SourceType | Aggregation Database Index Database Enrichment Source |
StartPage | 6660 |
SubjectTerms | ATP-Binding Cassette, Sub-Family B, Member 1 - antagonists & inhibitors ATP-Binding Cassette, Sub-Family B, Member 1 - biosynthesis ATP-Binding Cassette, Sub-Family B, Member 1 - genetics ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism Biological and medical sciences Cell Line, Tumor Cell Membrane - metabolism Cell Movement - drug effects Cell Movement - physiology Dissemination Drug Resistance, Neoplasm Female Flupenthixol - pharmacology Humans Hyaluronan Receptors - biosynthesis Hyaluronan Receptors - genetics Hyaluronan Receptors - metabolism Immunoprecipitation Medical sciences Neoplasm Invasiveness Neoplasms - drug therapy Neoplasms - metabolism Neoplasms - pathology RNA Interference Transfection Tumor cell Tumors |
Title | The CD44 Receptor Interacts with P-Glycoprotein to Promote Cell Migration and Invasion in Cancer |
URI | https://www.ncbi.nlm.nih.gov/pubmed/16061646 https://www.proquest.com/docview/17403030 https://www.proquest.com/docview/68436401 |
Volume | 65 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKkBASmriODhh-4K1KycVJnMep7CJYC2it1LfguHZXLWuqNkViT_x0ji9JU6nTgJcosmJH8vfl5PhcEfoQ0DjxeRI4YRRnDhEed5gUnsM8LpMJ49LXzWD6g-h8RD6Pw3Gr9bsRtbQusy6_3ZlX8j-owhjgqrJk_wHZelEYgHvAF66AMFz_GuPeJ0I6ILbEotSh5SqjmFdJa9-caf6LF7oYgwpoLFQ8FoAjOspg37mZTS0BTA2mn2xlQx-5IsOyqbn29EjHFge60t5fE8ahxUyedxtGhT7ImrKcOWfF_Fa74r3cWKq_sGXeTH4wQu9SWXXsL1SDX16tr1Xst7HODoTI2bUyedRMvmTTfHaTCd2QqnM2W6_EYsGsX6kyYoR1CN1GMFMnJPGWYDZNJCoChg0xC2cud7f8D6kJmDSrdXvHA-36IaZP0Ha97cHX9HR0cZEOT8bDB-ihH4P2pdz63zf15kMbBFstaHPA4DUfd75kS7t5smAr-NCk6ZBy9xFGqzLDp2jfnkHwsSHUM9QS8-foUd9GWbxAP4BXWPEKV7zCNa-w4hXe5hUuC2x5hRWvcM0rDKDhildwgw2vXqLR6cmwd-7YThwOJ65fOhFzuTtJZMYCTgOeKF8rnPNlRqSgkXD9LOGuJEGmKgQmMCfmmZ-42SRU1YQoDV6hvXkxF68RljTkHkiBMJ54hBFJozjwXRKJREoqWNJGpNrBlNsy9apbSp7q42pIVbgETdXGp7DxqUtStfFt1K2nLUydlvsmHG3Bs5kVJVQ1JWij9xVeKYhctX1sLor1KoVDPPwaA_fuJyJKgoi4XhsdGKAbq4MCHZHo8N65b9DjzZfyFu2Vy7V4BwpwmR1pjv4B93Otog |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+CD44+receptor+interacts+with+P-glycoprotein+to+promote+cell+migration+and+invasion+in+cancer&rft.jtitle=Cancer+research+%28Chicago%2C+Ill.%29&rft.au=Miletti-Gonz%C3%A1lez%2C+Karl+E&rft.au=Chen%2C+Shiling&rft.au=Muthukumaran%2C+Neelakandan&rft.au=Saglimbeni%2C+Giuseppa+N&rft.date=2005-08-01&rft.issn=0008-5472&rft.volume=65&rft.issue=15&rft.spage=6660&rft_id=info:doi/10.1158%2F0008-5472.CAN-04-3478&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-5472&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-5472&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-5472&client=summon |